Search
From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A big pivotal is scheduled to read this year
Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A cell therapy program in melanoma will have a pivotal read this year, and Immatics also has bispecific programs and a second generation cell therapy under development.
21 hours ago
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews...
May 9, 2025
SITC 2024: Immatics CEO Harpreet Singh shares an update on clinical data presented at SITC for the company's Gen 1 and Gen 2 PRAME cell therapies
He describes the Gen 1 data in melanoma and more, and compares it to what we have seen with competitor TIL data. Also, why the Gen 2...
Nov 9, 2024
.png){kind=logo}
